7 Hills Pharma receives a $3 million SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop the first vaccine for Chagas disease. This innovative vaccine combination with 7HP349 aims to protect millions from the Trypanosoma cruzi parasite and prevent severe outcomes of the disease.

Researchers from the Texas Heart Institute, UTMB, and 7 Hills Pharma have pioneered a groundbreaking study on the use of 7HP349, an oral integrin activator, as a vaccine adjuvant. This research, published in Nature Partner Journal Vaccines, shows how 7HP349 enhances immune responses, with promising applications for Chagas disease and COVID-19 vaccines, particularly in immunocompromised individuals.